Genentech's early-stage development pipeline currently has over 15 new molecular entities in clinical development in the following therapeutic focus areas: oncology, immunology, disorders of tissue growth and repair, and neuroscience. Our R&D activities are focused on applying excellent science to discover and develop potential new medicines with the goal of becoming first-in-class or best-in-class therapeutics.

Please refer to the project links provided below for detailed information regarding the development status of a project.

Phase I
Oncology	ABT-263	Solid tumors and hematologic malignancies
	Anti-EGFL7	Solid tumors
	Anti-NRP1	Solid tumors
	Dulanermin	Metastatic colorectal cancer
	MEK Inhibitor (GDC-0973)	Solid tumors
	PI3 Kinase Inhibitor (GDC-0941)	Metastatic breast cancer Metastatic non-small cell lung cancer
	PI3 Kinase Inhibitor (GDC-0980)	Solid tumors and non-Hodgkin's lymphoma
Immunology	Anti-LT alpha	Rheumatoid arthritis
	rhuMAb Beta7	Ulcerative colitis
Tissue Growth & Repair	Anti-oxLDL	Secondary prevention of cardiovascular events
	BHT-3021	Type 1 diabetes
Neuroscience	Anti-Abeta	Alzheimer's Disease
Ophthalmology	Anti-Factor D	Geographic atrophy associated with age-related macular degeneration
Phase II
Oncology	ABT-263	Relapsed chronic lymphocytic leukemia Relapsed lymphoid malignancies Small cell lung cancer
	MetMAb	Second- and third-line metastatic non-small cell lung cancer
Immunology	Lebrikizumab	Asthma
	Rontalizumab	Systemic lupus erythematosus

Information updated February 2010